(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/21orldwECAc/story01.htm
Read More
No comments:
Post a Comment